Abstract:Influenza virus causes influenza, an infectious disease. The symptoms can range from mild to severe. Severe influenza infections have historically led to 250,000 to 500,000 deaths per year. Influenza viruses can be broadly classified into four types as A, B, C, and D. They are structurally similar, and place high demands on drugs. The heterotrimeric polymerase complex of the influenza virus represents a promising target for the design and improvement of novel lead compounds. Inhibition of its assembly could be proven to have an antiviral efficacy for both in vitro and in vivo activity. However, in vivo, potent lead compounds tackling this target have not been identified yet. In this study, we have used the information about two previously discovered molecules (referred to as ANA 1 and PAC-3), which revealed significant in vitro effects, and we have proposed new compounds using a computational protocol. Structural, chemical similarity calculations against the ZINC database were carried out using the Generic Match Algorithm (GMA). Putative inhibitor binding sites of the influenza virus polymerase were investigated based on the blind docking approach employing AutoDock Vina and Lead Finder. Furthermore, ligand-based virtual screenings were executed, calculating shape similarity using a Weighted Gaussian Algorithm (WEGA) and pharmacophoric properties by LigandScout. A handful of molecules were finally selected as promising inhibitors. The binding efficiency and the toxicity properties of the identified lead compound DB07972 (MolPort-002-025-261) were compared against the available drug of choice Baloxavir marboxil. The molecular dynamics simulations along with the MMPBSA calculations have shown that the novel lead compound DB07972 is capable of exhibiting better interaction and compactness. More interestingly, the novel lead compound was found to be less toxic than the control drug. The molecule was further evaluated using in vitro approaches. From the experimental analysis, the chosen compound, DB07972, showed maximal inhibition around 75% with 20 μM and was non-toxic to 100% healthy cells at the same concentration.

Construction of Anti-Influenza Virus Drug Selection Based on Protein-Protein Interaction among Polymerase Subunits

Screening of Proteins Interacting with PB1-F2 of Influenza A Virus Using Yeast Two-hybrid System from Human Leukocyte cDNA Library

Discovery of Multitarget-Directed Ligands Against Influenza A Virus From Compound Yizhihao Through a Predictive System for Compound-Protein Interactions

Identification of Novel Influenza Polymerase PB2 Inhibitors Using a Cascade Docking Virtual Screening Approach

Identification of influenza polymerase inhibitors targeting C-terminal domain of PA through surface plasmon resonance screening

Free energy calculations and binding analysis of two potential anti- influenza drugs with Polymerase basic protein-2 (PB2).

Identification of novel influenza polymerase PB2 inhibitors using virtual screening approach and molecular dynamics simulation analysis of active compounds

Identification of influenza polymerase inhibitors targeting polymerase PB2 cap-binding domain through virtual screening

Identification of a Small-Molecule Inhibitor of Influenza Virus Via Disrupting the Subunits Interaction of the Viral Polymerase.

Synthesis and Structure-Activity Optimization of 7-Azaindoles Containing Aza-Β-amino Acids Targeting the Influenza PB2 Subunit.

Prediction and characterization of influenza virus polymerase inhibitors through blind docking and ligand based virtual screening

Identification and in vivo Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity

Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit

Screening for Novel Small-Molecule Inhibitors Targeting the Assembly of Influenza Virus Polymerase Complex by A Bimolecular Luminescence Complementation-Based Reporter System

Virtual Screening and Molecular Dynamics Simulation Study of Influenza Polymerase PB2 Inhibitors

Rational Design and Optimization of Acylthioureas As Novel Potent Influenza Virus Non-Nucleoside Polymerase Inhibitors.

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

Glycopolymer with Sulfated Fucose and 6'-Sialyllactose as a Dual-Targeted Inhibitor on Resistant Influenza A Virus Strains

RNA interference against influenza A (H1N1) virus

Influenza A Virus Polymerase: an Attractive Target for Next-Generation Anti-Influenza Therapeutics

Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus